Research analysts who have asked questions during BIOSTEM TECHNOLOGIES earnings calls.
Erik Voss
Mission Vertical
2 questions for BSEM
BS
Bradley Sorensen
Analyst
1 question for BSEM
Bruce Jackson
The Benchmark Company LLC
1 question for BSEM
Also covers: BFRI, BLTE, CV +8 more
EW
Ernest Watts
Watts Associates
1 question for BSEM
Kevin
RBC Capital Markets
1 question for BSEM
Also covers: ARBK, CMPS, GHG +2 more
KP
Kevin Peterson
Petersen Capital
1 question for BSEM
Mitchell Sacks
Grand Slam
1 question for BSEM
PT
Page Taggart
APT Capital
1 question for BSEM
PT
Paige Taggart
APT Consulting
1 question for BSEM
PS
Peter Stoddard
Stoddard Investments
1 question for BSEM
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for BSEM
Also covers: ABSI, CGEN, CLGN +24 more
Recent press releases and 8-K filings for BSEM.
BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business
BSEM
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- BioStem Technologies has completed the acquisition of BioTissue Holdings' surgical and wound care business for an upfront cash payment of approximately $15 million, with potential additional regulatory milestone payments of up to $10 million and royalty milestone payments of up to $15 million.
- This acquisition doubles BioStem's addressable market by accelerating its entry into the acute wound care market, diversifying end markets, and expanding its product portfolio with brands like NEOX and Claryx.
- The acquired assets generated approximately $29 million in 2025 revenue with industry-standard 65% gross margins and are expected to be growth and EBITDA accretive for BioStem in 2026.
- The transaction includes the integration of BioTissue's experienced national sales force, comprising approximately 20 direct sales representatives and more than 30 independent sales agents, along with prominent Group Purchasing Organization (GPO) contracts.
- BioStem plans to transition the manufacturing of the acquired products in-house after a minimum of 12 months, which is expected to lead to gross margin expansion.
Jan 22, 2026, 1:00 PM
BioStem Technologies Completes Acquisition of BioTissue Holdings' Surgical and Wound Care Business
BSEM
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- BioStem Technologies (BSEM) completed the acquisition of BioTissue Holdings' surgical and wound care business, which doubles its addressable market and accelerates its entry into the acute wound care market.
- The acquired business generated approximately $29 million in 2025 revenue with 65% gross margins and is projected to be growth and EBITDA accretive for BioStem in 2026.
- The transaction involved an upfront cash payment of approximately $15 million, with potential future payments including up to $10 million for 510(k) clearance of a pipeline product and royalty milestones up to $15 million.
- Post-closing, BioStem's cash and equivalents balance is approximately $16 million.
- The acquisition also integrates BioTissue's national sales force, comprising approximately 20 direct sales representatives and over 30 independent sales agents, and includes prominent Group Purchasing Organization (GPO) contracts.
Jan 22, 2026, 1:00 PM
BioStem Technologies Completes Acquisition of BioTissue Holdings' Surgical and Wound Care Business
BSEM
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- BioStem Technologies has completed the acquisition of BioTissue Holdings' surgical and wound care business for an upfront cash payment of approximately $15 million.
- This acquisition is expected to double BioStem's addressable market by accelerating its entry into the acute wound care market, expanding its product portfolio with the NEOX and Claryx product families, and extending its geographic commercial footprint.
- The acquired assets generated approximately $29 million in 2025 revenue with industry-standard gross margins of 65% and are expected to be growth and EBITDA accretive for BioStem in 2026.
- The transaction includes the integration of BioTissue's experienced national sales force, comprising approximately 20 direct sales representatives and more than 30 independent sales agents, and prominent group purchasing organization (GPO) contracts.
- BioStem's cash and equivalents balance post-closing is approximately $16 million, with the initial $15 million payment funded from cash on hand.
Jan 22, 2026, 1:00 PM
BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business
BSEM
M&A
New Projects/Investments
Product Launch
- BioStem Technologies, Inc. (OTC: BSEM) completed the acquisition of BioTissue Holdings, Inc.'s non-ocular Surgical and Wound Care business.
- This acquisition grants BioStem exclusive rights to the Neox® and Clarix® product lines.
- BioTissue's Surgical sales team and key support staff will integrate into BioStem's commercial organization, while BioTissue will continue to manufacture the acquired products for BioStem.
- BioStem's CEO, Jason Matuszewski, noted that BioTissue's strengths complement their existing business, presenting a significant opportunity for investment in commercial execution to drive growth.
Jan 21, 2026, 11:00 PM
BioStem Technologies Reports Record Q4 2024 Financial Performance
BSEM
Earnings
Revenue Acceleration/Inflection
Product Launch
- Q4 revenue reached $102.9 million, up significantly from $11.5 million in Q4 2023, driving full‑year revenue to $301.8 million with positive GAAP net income, reflecting strong operational execution.
- The company achieved robust market impact with the nationwide launch of VENDAJE AC and strong adoption of AmnioWrap2, positioning its clinical trials and strategic initiatives for continued growth in 2025.
- BioStem is advancing its strategic initiatives with progress on uplisting to NASDAQ and an improved cash balance of $22.8 million at Q4 end, underpinning its future expansion efforts.
Apr 14, 2025, 8:31 PM
Quarterly earnings call transcripts for BIOSTEM TECHNOLOGIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more